Search - tctmd.com

Displaying 741 - 760 of 2546

Sort: Relevancy | Date

Presentation TCT 2019

Best Practices in Animal Studies of Cardiovascular Devices: What Does the FDA Look For?

Presenter: Natalie Miller

September 28, 2019

Presentation TCT 2019

Trial Design for Tricuspid Devices: Perspectives From the FDA

Presenter: Jaime Raben

September 28, 2019

Presentation TCT 2019

Device-Based Autonomic Modulation in Supraventricular and Ventricular Arrhythmias

Presenter: Christian Ukena

September 28, 2019

Presentation TCT 2019

Device-Based Autonomic Modulation in Heart Failure

Presenter: Michael Boehm

September 28, 2019

Presentation TCT 2019

Best Practices in Biocompatibility Assessment of Cardiovascular Devices: What Does the FDA Look For?

Presenter: Claire Hambright

September 28, 2019

Presentation TCT 2019

What Are the Essential Differences Between Renal Denervation Devices and Procedures, and Do They Matter?

Presenter: Philipp Lurz

September 28, 2019

Presentation TCT 2019

Innovative Trial Designs in Device-Based Hypertension Treatment

Presenter: Konstantinos Tsioufis

September 28, 2019

Debate: Is a Clinical Outcomes Trial Mandatory Before Widespread Adoption of Device-Based Hypertension Therapies? - Yes, An Outcomes Study for Device-Based Hypertension Approaches Is Needed Before Widespread Use Can Be Recommended!

Presentation TCT 2019

Yes, An Outcomes Study for Device-Based Hypertension Approaches Is Needed Before Widespread Use Can Be Recommended!

Presenter: Bernard Gersh

September 28, 2019

Debate: Is a Clinical Outcomes Trial Mandatory Before Widespread Adoption of Device-Based Hypertension Therapies? - No: An Outcomes Study for Device-Based Hypertension Approaches Is NOT Necessary Before Widespread Use Can Be Recommended!

Presentation TCT 2019

No: An Outcomes Study for Device-Based Hypertension Approaches Is NOT Necessary Before Widespread Use Can Be Recommended!

Presenter: Andrew Sharp

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

Presentation TCT 2019

Device-Based Hypertension Treatments: Defining Responders and Predictors of Response

Presenter: Naomi Fisher

September 28, 2019

Presentation TCT 2019

Backbeat Update (Pacemaker-Mediated Baroreflex Stimulation)

Presenter: Daniel Burkhoff

September 28, 2019

Presentation TCT 2019

Update on ROX Trial Program (AV Fistula Creation)

Presenter: Melvin Lobo

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

Presentation TCT 2019

Update on CALM-II Trial (Endovascular Baroreflex Stimulation)

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

Magnitude of Antihypertensive Effect After Renal Denervation: Is It Sufficient for High-Risk as Well as Low-Risk Patients?

Presenter: Justin Davies

September 28, 2019

Presentation TCT 2019

Transcatheter Annular Devices: Overview and Outcomes

Presenter: Georg Nickenig

September 28, 2019

Presentation TCT 2019

Update on Target BP Trials Program (Chemical Renal Denervation): Lessons Learned, Ongoing Efforts

Presenter: Felix Mahfoud

September 28, 2019

Presentation TCT 2019

The Future: Imaging-Based Algorithm for Device Selection in Coronary Calcium

Presenter: Akiko Maehara

September 28, 2019

Presentation TCT 2019

Update on RADIANCE Trials Program (Ultra-Sound Renal Denervation): Lessons Learned, Ongoing Efforts

Presenter: Ajay Kirtane

September 28, 2019

Advertisement

Best Practices in Animal Studies of Cardiovascular Devices: What Does the FDA Look For?

Trial Design for Tricuspid Devices: Perspectives From the FDA

Device-Based Autonomic Modulation in Supraventricular and Ventricular Arrhythmias

Device-Based Autonomic Modulation in Heart Failure

Best Practices in Biocompatibility Assessment of Cardiovascular Devices: What Does the FDA Look For?

What Are the Essential Differences Between Renal Denervation Devices and Procedures, and Do They Matter?

Innovative Trial Designs in Device-Based Hypertension Treatment

Yes, An Outcomes Study for Device-Based Hypertension Approaches Is Needed Before Widespread Use Can Be Recommended!

No: An Outcomes Study for Device-Based Hypertension Approaches Is NOT Necessary Before Widespread Use Can Be Recommended!

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Device-Based Hypertension Treatments: Defining Responders and Predictors of Response

Backbeat Update (Pacemaker-Mediated Baroreflex Stimulation)

Update on ROX Trial Program (AV Fistula Creation)

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Update on CALM-II Trial (Endovascular Baroreflex Stimulation)

Magnitude of Antihypertensive Effect After Renal Denervation: Is It Sufficient for High-Risk as Well as Low-Risk Patients?

Transcatheter Annular Devices: Overview and Outcomes

Update on Target BP Trials Program (Chemical Renal Denervation): Lessons Learned, Ongoing Efforts

The Future: Imaging-Based Algorithm for Device Selection in Coronary Calcium

Update on RADIANCE Trials Program (Ultra-Sound Renal Denervation): Lessons Learned, Ongoing Efforts

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content